111In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas

被引:21
作者
Deutscher, Susan L. [1 ,2 ]
Figueroa, Said D. [2 ]
Kumar, Senthil R. [1 ,2 ]
机构
[1] Univ Missouri, Dept Biochem, Sch Med, Columbia, MO 65211 USA
[2] Harry S Truman Mem Vet Hosp, Div Res, Columbia, MO 65201 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; ErbB-2; peptide; radiolabeling; imaging; MONOCLONAL-ANTIBODY FRAGMENTS; RENAL UPTAKE; CANCER; INTERNALIZATION; OVEREXPRESSION; EXPRESSION; BREAST; ERBB2; IDENTIFICATION; NIH-OVCAR-3;
D O I
10.1002/jlcr.1691
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Aberrant expression of ErbB-2, a member of the epidermal growth factor family of receptors, has been implicated in the formation of various malignancies including ovarian cancer. The objective of this study was to determine whether the phage display-selected ErbB-2 targeting peptide, KCCYSL, once radiolabeled with In-111 would serve as a tumor targeting and single photon emission computed tomography (SPECT/CT) imaging agent in a mouse model of human ovarian carcinoma expressing ErbB-2. The KCCYSL peptide was synthesized with a chelator 1,4,7,10-tetra-azacyclododecane-N,N',N '',N '''-tetraacetic acid (DOTA), and a Gly-Ser-Gly (GSG) spacer between DOTA and amino terminus of the peptide and radiolabeled with (InCl3)-In-111. In vitro cell binding studies indicated that In-111-DOTA-GSG-KCCYSL bound to cultured ovcar-3 carcinoma cells. Bio-distribution studies in scid mice bearing human ovcar-3 tumor xenografts revealed a tumor uptake of 0.50 +/- 0.05 percent injected dose per gram (%ID/g) at 1 h, and 0.39 +/- 0.1 %ID/g at 2h. Blocking studies with non-radiolabeled counterpart indicated a partial inhibition (41%) (P = 0.04) in tumor uptake of In-111-DOTA-GSG-KCCYSL. In vivo tumor uptake of In-111-DOTA-GSG-KCCYSL was clearly evident through SPECT/CT images after 2 h post injection. These studies suggest the potential of this peptide as a radiopharmaceutical for imaging of ErbB-2-expressing ovarian tumors.
引用
收藏
页码:583 / 590
页数:8
相关论文
共 41 条
[1]   INVIVO APPLICATION OF [IN-111-DTPA-D-PHE1]-OCTREOTIDE FOR DETECTION OF SOMATOSTATIN RECEPTOR-POSITIVE TUMORS IN RATS [J].
BAKKER, WH ;
KRENNING, EP ;
REUBI, JC ;
BREEMAN, WAP ;
SETYONOHAN, B ;
DEJONG, M ;
KOOIJ, PPM ;
BRUNS, C ;
VANHAGEN, PM ;
MARBACH, P ;
VISSER, TJ ;
PLESS, J ;
LAMBERTS, SWJ .
LIFE SCIENCES, 1991, 49 (22) :1593-1601
[2]   THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
NATURE, 1986, 319 (6050) :226-230
[3]   Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations [J].
Behr, TM ;
Goldenberg, DM ;
Becker, W .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :201-212
[4]  
BEHR TM, 1995, CANCER RES, V55, P3825
[5]  
Behr TM, 1996, J NUCL MED, V37, P829
[6]  
Chen JQ, 2000, CANCER RES, V60, P5649
[7]  
CHO KR, 2000, ANNU REV PATHOL-MECH, V4, P287
[8]   Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy [J].
Citri, A ;
Alroy, I ;
Lavi, S ;
Rubin, C ;
Xu, WP ;
Grammatikakis, N ;
Patterson, C ;
Neckers, L ;
Fry, DW ;
Yarden, Y .
EMBO JOURNAL, 2002, 21 (10) :2407-2417
[9]  
FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO
[10]  
2-8